D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic
Research output: Book/Report › Report › Research
Standard
D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic. / Vogt, Henrik; Gaillard, Maxence; Green, Sara.
CORDIS EU research results, 2023. 79 p.Research output: Book/Report › Report › Research
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - RPRT
T1 - D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic
AU - Vogt, Henrik
AU - Gaillard, Maxence
AU - Green, Sara
PY - 2023
Y1 - 2023
N2 - Organoids and organ-on-chip (OoC) are new and emerging technologies (NESTs) that are promised to bring great improvements to clinical practice in the form of personalized or precision medicine (PM). “Traditional” health technology assessments (HTAs) have in the past been focused on assessing the clinical evidence for technologies that already exist and have been studied in trials, but such a methodology runs into problems when assessing technologies that so far mostly exist as visions for the future. This takes another kindof amended health technology assessment method. In this report we develop such a technology assessment method for assessing organoids and OoCs as emerging technologies used directly in patient management in the clinic. We search for and review a heterogeneous literature on how to assess NESTs and scientific visions, extract from this literature methodological elements that suit our purpose and add fitfor-purpose elements that we could not find in the literature. The developed vision assessment method is both intended as for the next (D2.4) HYBRIDA report, where we apply it to assess visions for clinical applications of organoids and OoCsin PM, and as a contribution to methodological development in health technology more generally.
AB - Organoids and organ-on-chip (OoC) are new and emerging technologies (NESTs) that are promised to bring great improvements to clinical practice in the form of personalized or precision medicine (PM). “Traditional” health technology assessments (HTAs) have in the past been focused on assessing the clinical evidence for technologies that already exist and have been studied in trials, but such a methodology runs into problems when assessing technologies that so far mostly exist as visions for the future. This takes another kindof amended health technology assessment method. In this report we develop such a technology assessment method for assessing organoids and OoCs as emerging technologies used directly in patient management in the clinic. We search for and review a heterogeneous literature on how to assess NESTs and scientific visions, extract from this literature methodological elements that suit our purpose and add fitfor-purpose elements that we could not find in the literature. The developed vision assessment method is both intended as for the next (D2.4) HYBRIDA report, where we apply it to assess visions for clinical applications of organoids and OoCsin PM, and as a contribution to methodological development in health technology more generally.
UR - https://cordis.europa.eu/project/id/101006012/results
M3 - Report
BT - D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic
PB - CORDIS EU research results
ER -
ID: 340687136